VATHLT8310 - The zero rate for free-of-charge medicines: Clinical trials: Medicines supplied for use in a clinical trial
Where a medicinal product is used in the course of a clinical trial that has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), this will be either an investigational medicinal product or a non-investigational medicinal product. Both are zero-rated when supplied for use in a clinical trial.
The clinical trial does not need to be an NHS-funded or NHS-supported clinical trial, and it does not need to take place in an NHS hospital.
All investigational medicinal products and non-investigational medicinal products that are required for use in the clinical trial will qualify for the zero-rating when they are supplied for use in that clinical trial. This includes those used for the control arm of the trial, and those which are not the main product which is the subject of the trial.
Prior to 23 June 2026, such supplies for use in clinical trials may be treated as samples; therefore no output tax is due for medicines which were used during clinical trials. This means that the input tax is recoverable, and no output tax is due. This has the same practical effect as a zero rate.
Between 23 June 2026 and the date of Royal Assent to the Finance Act 2027, suppliers can continue to treat these as samples, or they can apply the zero rate. The same amount of input tax is recoverable either way, and no output tax is due either way.
From Royal Assent to the Finance Act 2027, these should be treated as zero-rated. This means the supplier will continue to recover input tax as though they were treating the products as samples, and continue to not account for output tax.
After a trial has concluded, a medicinal product that was used as either an investigational medicinal product or a non-investigational medicinal product for the treatment of a patient in the trial can continue to be supplied free of charge for the treatment of that patient. This supply may be zero-rated, provided it is the same product as the patient received during the trial (see VATHLT8320).